Schat K A, Murthy K K
J Virol. 1980 Apr;34(1):130-5. doi: 10.1128/JVI.34.1.130-135.1980.
Marek's disease tumor-associated surface antigen (MATSA) has been claimed to be the target of cytotoxic lymphocytes in in vitro tests for Marek's disease immunity. Treatment with papain, but not with trypsin or mixed glycosidases, removed MATSA from certain Marek's disease lymphoblastoid cell lines. Tumor cells with and without MATSA were used as target cells for in vitro studies on cell-mediated immune responses with sensitized spleen cells in a chromium release assay. The removal of MATSA did not influence the results of the chromium release assay. Attempts to block the cell-mediated cytotoxicity in vitro by coating tumor cells with an anti-MATSA serum failed. It was concluded that cell-mediated immune responses against Marek's disease tumor cells are directed against an as yet undefined antigen(s).
在马立克氏病免疫的体外试验中,马立克氏病肿瘤相关表面抗原(MATSA)被认为是细胞毒性淋巴细胞的靶标。用木瓜蛋白酶处理,而非胰蛋白酶或混合糖苷酶处理,可从某些马立克氏病淋巴母细胞系中去除MATSA。有无MATSA的肿瘤细胞被用作靶细胞,用于在铬释放试验中用致敏脾细胞进行细胞介导免疫反应的体外研究。MATSA的去除并不影响铬释放试验的结果。用抗MATSA血清包被肿瘤细胞来体外阻断细胞介导的细胞毒性的尝试失败了。得出的结论是,针对马立克氏病肿瘤细胞的细胞介导免疫反应针对的是一种尚未明确的抗原。